208 related articles for article (PubMed ID: 10052961)
1. Dual inhibition of phosphodiesterase 4 and matrix metalloproteinases by an (arylsulfonyl)hydroxamic acid template.
Groneberg RD; Burns CJ; Morrissette MM; Ullrich JW; Morris RL; Darnbrough S; Djuric SW; Condon SM; McGeehan GM; Labaudiniere R; Neuenschwander K; Scotese AC; Kline JA
J Med Chem; 1999 Feb; 42(4):541-4. PubMed ID: 10052961
[No Abstract] [Full Text] [Related]
2. Design and synthesis of cyclic inhibitors of matrix metalloproteinases and TNF-alpha production.
Xue CB; He X; Roderick J; DeGrado WF; Cherney RJ; Hardman KD; Nelson DJ; Copeland RA; Jaffee BD; Decicco CP
J Med Chem; 1998 May; 41(11):1745-8. PubMed ID: 9599225
[No Abstract] [Full Text] [Related]
3. Design and synthesis of phosphinamide-based hydroxamic acids as inhibitors of matrix metalloproteinases.
Pikul S; McDow Dunham KL; Almstead NG; De B; Natchus MG; Anastasio MV; McPhail SJ; Snider CE; Taiwo YO; Chen L; Dunaway CM; Gu F; Mieling GE
J Med Chem; 1999 Jan; 42(1):87-94. PubMed ID: 9888835
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of matrix metalloproteinases by peptidyl hydroxamic acids.
Odake S; Morita Y; Morikawa T; Yoshida N; Hori H; Nagai Y
Biochem Biophys Res Commun; 1994 Mar; 199(3):1442-6. PubMed ID: 8147888
[TBL] [Abstract][Full Text] [Related]
5. Modulation of matrix metalloproteinase production from human lung fibroblasts by type 4 phosphodiesterase inhibitors.
Martin-Chouly CA; Astier A; Jacob C; Pruniaux MP; Bertrand C; Lagente V
Life Sci; 2004 Jul; 75(7):823-40. PubMed ID: 15183075
[TBL] [Abstract][Full Text] [Related]
6. Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF alpha inhibitory activity of two series of rolipram analogues: implications for a new active site model of PDE4.
Kleinman EF; Campbell E; Giordano LA; Cohan VL; Jenkinson TH; Cheng JB; Shirley JT; Pettipher ER; Salter ED; Hibbs TA; DiCapua FM; Bordner J
J Med Chem; 1998 Jan; 41(3):266-70. PubMed ID: 9464356
[No Abstract] [Full Text] [Related]
7. Discovery of potent, achiral matrix metalloproteinase inhibitors.
Pikul S; McDow Dunham KL; Almstead NG; De B; Natchus MG; Anastasio MV; McPhail SJ; Snider CE; Taiwo YO; Rydel T; Dunaway CM; Gu F; Mieling GE
J Med Chem; 1998 Sep; 41(19):3568-71. PubMed ID: 9733482
[No Abstract] [Full Text] [Related]
8. N-Aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases: further probing of the S(1), S(1)', and S(2)' pockets.
Hanessian S; Moitessier N; Gauchet C; Viau M
J Med Chem; 2001 Sep; 44(19):3066-73. PubMed ID: 11543675
[TBL] [Abstract][Full Text] [Related]
9. 3-Hydroxy-4-arylsulfonyltetrahydropyranyl-3-hydroxamic acids are novel inhibitors of MMP-13 and aggrecanase.
Noe MC; Snow SL; Wolf-Gouveia LA; Mitchell PG; Lopresti-Morrow L; Reeves LM; Yocum SA; Liras JL; Vaughn M
Bioorg Med Chem Lett; 2004 Sep; 14(18):4727-30. PubMed ID: 15324896
[TBL] [Abstract][Full Text] [Related]
10. Discovery of thiadiazoles as a novel structural class of potent and selective PDE7 inhibitors. Part 1: design, synthesis and structure-activity relationship studies.
Vergne F; Bernardelli P; Lorthiois E; Pham N; Proust E; Oliveira C; Mafroud AK; Royer F; Wrigglesworth R; Schellhaas J; Barvian M; Moreau F; Idrissi M; Tertre A; Bertin B; Coupe M; Berna P; Soulard P
Bioorg Med Chem Lett; 2004 Sep; 14(18):4607-13. PubMed ID: 15324874
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships.
Ko WC; Shih CM; Lai YH; Chen JH; Huang HL
Biochem Pharmacol; 2004 Nov; 68(10):2087-94. PubMed ID: 15476679
[TBL] [Abstract][Full Text] [Related]
12. Solid-phase synthesis of an arylsulfone hydroxamate library.
Salvino JM; Mathew R; Kiesow T; Narensingh R; Mason HJ; Dodd A; Groneberg R; Burns CJ; McGeehan G; Kline J; Orton E; Tang SY; Morrisette M; Labaudininiere R
Bioorg Med Chem Lett; 2000 Aug; 10(15):1637-40. PubMed ID: 10937713
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of stromelysin-1 (MMP-3) by P1'-biphenylylethyl carboxyalkyl dipeptides.
Esser CK; Bugianesi RL; Caldwell CG; Chapman KT; Durette PL; Girotra NN; Kopka IE; Lanza TJ; Levorse DA; MacCoss M; Owens KA; Ponpipom MM; Simeone JP; Harrison RK; Niedzwiecki L; Becker JW; Marcy AI; Axel MG; Christen AJ; McDonnell J; Moore VL; Olszewski JM; Saphos C; Visco DM; Hagmann WK
J Med Chem; 1997 Mar; 40(6):1026-40. PubMed ID: 9083493
[TBL] [Abstract][Full Text] [Related]
14. Structure-based design and synthesis of a series of hydroxamic acids with a quaternary-hydroxy group in P1 as inhibitors of matrix metalloproteinases.
Jacobson IC; Reddy PG; Wasserman ZR; Hardman KD; Covington MB; Arner EC; Copeland RA; Decicco CP; Magolda RL
Bioorg Med Chem Lett; 1998 Apr; 8(7):837-42. PubMed ID: 9871551
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.
Aranapakam V; Grosu GT; Davis JM; Hu B; Ellingboe J; Baker JL; Skotnicki JS; Zask A; DiJoseph JF; Sung A; Sharr MA; Killar LM; Walter T; Jin G; Cowling R
J Med Chem; 2003 Jun; 46(12):2361-75. PubMed ID: 12773041
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and evaluation of a novel series of phosphodiesterase IV inhibitors. A potential treatment for asthma.
Beasley SC; Cooper N; Gowers L; Gregory JP; Haughan AF; Hellewell PG; Macari D; Miotla J; Montana JG; Morgan T; Naylor R; Runcie KA; Tuladhar B; Warneck JB
Bioorg Med Chem Lett; 1998 Oct; 8(19):2629-34. PubMed ID: 9873593
[TBL] [Abstract][Full Text] [Related]
17. Highly potent PDE4 inhibitors with therapeutic potential.
Ochiai H; Ohtani T; Ishida A; Kusumi K; Kato M; Kohno H; Odagaki Y; Kishikawa K; Yamamoto S; Takeda H; Obata T; Nakai H; Toda M
Bioorg Med Chem; 2004 Sep; 12(17):4645-65. PubMed ID: 15358291
[TBL] [Abstract][Full Text] [Related]
18. Discovery of hydroxamic acid analogs as dual inhibitors of phosphodiesterase-1 and -5.
Dan A; Shiyama T; Yamazaki K; Kusunose N; Fujita K; Sato H; Matsui K; Kitano M
Bioorg Med Chem Lett; 2005 Sep; 15(18):4085-90. PubMed ID: 16005625
[TBL] [Abstract][Full Text] [Related]
19. Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension.
Schermuly RT; Kreisselmeier KP; Ghofrani HA; Samidurai A; Pullamsetti S; Weissmann N; Schudt C; Ermert L; Seeger W; Grimminger F
Circ Res; 2004 Apr; 94(8):1101-8. PubMed ID: 15031263
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and molecular modeling study of iminodiacetyl monohydroxamic acid derivatives as MMP inhibitors.
Santos MA; Marques SM; Tuccinardi T; Carelli P; Panelli L; Rossello A
Bioorg Med Chem; 2006 Nov; 14(22):7539-50. PubMed ID: 16875829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
